Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
AbCellera Biologics Inc. (ABCL) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/12/2023 8-K Quarterly results
08/03/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/03/2023 8-K Quarterly results
Docs: "AbCellera Biologics Inc. Condensed Consolidated Statements of Income and",
"CO PY RI GH T"
05/24/2023 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "NEWS RELEASE AbCellera Partners with the Governments of Canada and British Columbia to Advance Drug Development Capabilities and Infrastructure"
05/04/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/04/2023 8-K Quarterly results
04/28/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/28/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/28/2023 ARS Form ARS - Annual Report to Security Holders:
04/24/2023 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
02/21/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
02/21/2023 10-K Annual Report for the period ended December 31, 2022
02/13/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/06/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
01/18/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
11/08/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/08/2022 8-K Quarterly results
07/22/2022 10-K/A Annual Report for the period ended December 31, 2021 [amend]
07/22/2022 POS AM Form POS AM - Post-Effective amendments for registration statement:
07/06/2022 8-K Quarterly results
06/30/2022 8-K Quarterly results
06/21/2022 8-K Quarterly results
05/10/2022 10-Q Quarterly Report for the period ended March 31, 2022
05/10/2022 8-K Quarterly results
04/28/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/28/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
02/25/2022 S-3ASR Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers:
02/25/2022 POS AM Form POS AM - Post-Effective amendments for registration statement:
02/25/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
02/25/2022 10-K Annual Report for the period ended December 31, 2021
02/24/2022 8-K Quarterly results
02/15/2022 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
02/15/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Left: Side view of a model of bebtelovimab Fabs bound to SARS-CoV-2 spike protein mapped with key mutations from the Omicron variant of concern . Right:"
02/14/2022 SC 13G/A VIKING GLOBAL INVESTORS LP reports a 0% stake in AbCellera Biologics Inc.
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy